Cambridge, MA, United States of America

Liming Zhang

This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liming Zhang. Retrieved from https://idiyas.com/inventor/liming-zhang-e4i6e1ws

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liming Zhang: Innovator in Pharmacokinetics

Introduction

Liming Zhang is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmacokinetics, particularly through his innovative patent.

Latest Patents

Liming Zhang holds a patent titled "Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof." This patent describes compositions that include methyl 3-((methyl sulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, along with an agent for reducing metabolism of the compound and its various uses. He has 1 patent to his name.

Career Highlights

Liming Zhang is currently associated with Takeda Pharmaceutical Company Limited, where he continues to work on advancing pharmaceutical innovations. His expertise in pharmacokinetics has positioned him as a valuable asset in the field.

Collaborations

Throughout his career, Liming Zhang has collaborated with notable colleagues, including Mark Rogge and Hélène Faessel. These collaborations have further enriched his research and contributions to the pharmaceutical industry.

Conclusion

Liming Zhang is a distinguished inventor whose work in pharmacokinetics has led to significant advancements in the field. His innovative patent and collaborations highlight his commitment to improving pharmaceutical outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…